Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
06/01/18Seres Therapeutics to Present at Two Upcoming June Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: Jefferies 2018 Global Healthcare Conference: a corporate overview will be presented on Wednesday, June 6 at 4:30 p.m. ET in New York, NY. Goldman Sachs 39th Annual Global Healthcare Conference: a corporate overview will be ... 
 Printer Friendly Version
05/17/18Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY. The event will feature presentations from Seres management and leading academic subject matter experts on the microbiome as a new therapeutic target, with a focus on the Seres pipeline and the opportunity for ... 
 Printer Friendly Version
05/09/18Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
– Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treatments; initiation of clinical study in metastatic melanoma planned for later this year – – FDA dialogue ongoing to support development of SER-287 for Ulcerative Colitis; Company plans to initiate clinical trial in mid-2018 – – Company to host Microbiome R&D Day on May 24 in New York City – ... 
 Printer Friendly Version
05/07/18Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 9, 2018 at 8:30 a.m. ET to discuss first quarter 2018 financial results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 1599207. ... 
 Printer Friendly Version
05/04/18Seres Therapeutics to Present at Two Upcoming May Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will attend each of the following upcoming healthcare conferences: Deutsche Bank 43rd Annual Health Care Conference: The company will participate in 1x1 meetings on Wednesday, May 9 in Boston, Mass. Bank of America Merrill Lynch 2018 Health Care Conference: The company will present a corporate ... 
 Printer Friendly Version
04/17/18Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (leveraging gut microbiota to impact tumor immunotherapy)1 will be presented today by Sceneay et al in the late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting (AACR) in Chicago. The data presen... 
 Printer Friendly Version
03/09/18Seres Therapeutics to Present at Two Upcoming March Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: The 38th Annual Cowen & Co. Health Care Conference: a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA. Oppenheimer's 28th Annual Healthcare Conference: a corporate overview wil... 
 Printer Friendly Version
03/08/18Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
- Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 - - Preliminary Phase 1b study data obtained for SER-262, the first ever rationally-designed fermented microbiome therapeutic candidate evaluated in humans– - Collaboration with MD Anderson and Parker Institute intends to initiate clinical study in 2018 to evaluate microbiome therapeutic... 
 Printer Friendly Version
03/02/18Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 8, 2018 at 8:00 a.m. ET to discuss fourth quarter 2017 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5092388. To joi... 
 Printer Friendly Version
01/31/18Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2018-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced the appointment of Eric D. Shaff to the additional role of Chief Operating Officer. Mr. Shaff has been Executive Vice President and Chief Financial Officer since joining the Company in November 2014, and he will continue to retain both positions. Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres, commented: “Eric h... 
 Printer Friendly Version
01/04/18Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
- Microbiome analyses demonstrate engraftment of SER-287-derived bacteria; microbiome compositional changes correlate with clinical remission - - SER-287 engraftment maintained four weeks after completion of dosing - - Company to discuss proposed SER-287 development plan with FDA and intends to initiate next clinical trial in mid-2018 - - FDA granted SER-287 Orphan Drug designation for treatment of pediatric UC patie... 
 Printer Friendly Version
01/04/18Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT. A live audio webcast of the presentation and breakout question and answer session will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become av... 
 Printer Friendly Version